source
- FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vaxStrain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.
- Regeneron halts Phase 1/2a uveitis trial of anti-CD3 antibody after safety eventRegeneron announced it is voluntarily ending the Phase 1/2a TITAN study of its anti‑CD3 monoclonal antibody, REGN7041, which was being evaluated for non‑infectious posterior uveitis. The decision…